Search
Selected Filters
Displaying 11–20 of 385 news results
-
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Research NewsPotential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
-
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
Research NewsFirst-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP
-
Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
Research NewsFirst patient shows vision improvements with a good safety profile.
-
SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)
Research NewsNovel neuroprotective approach could benefit RP patients regardless of genetic mutation
-
Research News
Marking an important milestone for this rare form of retinitis pigmentosa (RP)
-
AAVantgarde Completes Enrollment in Retinal Gene Therapy Trial for Usher Syndrome Type 1B
Research NewsMilestone brings hope to patients with rare inherited retinal disease
-
Research News
First patient treated in Part B of ASTRA trial evaluating SB-007.
-
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Beacon Therapeutics Launches Clinical Trial for Bilateral Administration of XLRP Gene Therapy
Research NewsThe company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
